Company intelligence / Profile preview

Cantargia AB

Ownership: Public · CANTA
Employees: ~22
Development stage: Phase 2

Overview

Cantargia’s lead asset nadunolimab (CAN04) is in Phase II trials for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. CAN10 entered clinical development in 2023 targeting autoimmune/inflammatory indications. Recent results show positive safety/biomarker data for CAN10 and efficacy signals in multiple cancers with nadunolimab combined with chemotherapy.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

6 assets

nadunolimab

5 more assets in the full pipeline.

Request access →

Partnerships

Patheon Biologics B.V. & BioWa Inc. – manufacturing/production of CAN04GEICAM – Spanish breast cancer group collaboration

Beyond the preview

Go deeper on Cantargia AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cantargia AB.

Explore the full profile